# BIOGEN INC. (BIIB) FY2024 Annual P&L / Income Statement - Company: BIOGEN INC. (BIIB) - Period: 2024-01-01 to 2024-12-31 - Filing: FY2024 10-K, filed 2025-02-12, accession number 0000875045-25-000009 - Page: https://plicit.ai/financials/biib/fy2024-annual-income-statement - Chart image: https://plicit.ai/charts/biib-fy2024-annual-income-statement-sankey.png ## Chart details: Revenue by Product and Service by Geography Income statement for 2024-01-01 through 2024-12-31. View: Product and Service by Geographical. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,675,900,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,310,400,000 US dollars - **Gross profit (calculated)**: 7,365,500,000 US dollars - **Operating expenses (calculated)**: 5,459,500,000 US dollars - **Operating profit (calculated)**: 1,906,000,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax**: 1,906,000,000 US dollars - **Income tax (benefit) expense**: 273,800,000 US dollars - **Net income**: 1,632,200,000 US dollars - **AVONEX - UNITED STATES**: 451,300,000 US dollars - **AVONEX - Rest of World**: 256,200,000 US dollars - **BENEPALI - UNITED STATES**: 0 US dollars - **BENEPALI - Rest of World**: 479,100,000 US dollars - **BYOOVIZ - UNITED STATES**: 23,000,000 US dollars - **BYOOVIZ - Rest of World**: 13,600,000 US dollars - **Subtotal: Biosimilars - UNITED STATES**: 24,100,000 US dollars - **Subtotal: Biosimilars - Rest of World**: 769,000,000 US dollars - **FAMPYRA - UNITED STATES**: 0 US dollars - **FAMPYRA - Rest of World**: 71,700,000 US dollars - **FLIXABI - UNITED STATES**: 0 US dollars - **FLIXABI - Rest of World**: 63,200,000 US dollars - **FUMADERM And ADUHELM - UNITED STATES**: 2,800,000 US dollars - **FUMADERM And ADUHELM - Rest of World**: 7,500,000 US dollars - **Total Fumarate - UNITED STATES**: 707,800,000 US dollars - **Total Fumarate - Rest of World**: 887,300,000 US dollars - **IMRALDI - UNITED STATES**: 0 US dollars - **IMRALDI - Rest of World**: 213,100,000 US dollars - **Total Interferon - UNITED STATES**: 562,700,000 US dollars - **Total Interferon - Rest of World**: 405,300,000 US dollars - **Subtotal: Multiple Sclerosis - UNITED STATES**: 2,190,500,000 US dollars - **Subtotal: Multiple Sclerosis - Rest of World**: 2,159,300,000 US dollars - **Other - UNITED STATES**: 75,000,000 US dollars - **Other - Rest of World**: 7,500,000 US dollars - **PLEGRIDY - UNITED STATES**: 111,400,000 US dollars - **PLEGRIDY - Rest of World**: 149,100,000 US dollars - **QALSODY - UNITED STATES**: 20,900,000 US dollars - **QALSODY - Rest of World**: 11,500,000 US dollars - **Subtotal: Rare Disease - UNITED STATES**: 947,700,000 US dollars - **Subtotal: Rare Disease - Rest of World**: 1,040,400,000 US dollars - **Completed technology for SKYCLARYS (U.S.) - UNITED STATES**: 301,100,000 US dollars - **Completed technology for SKYCLARYS (U.S.) - Rest of World**: 81,400,000 US dollars - **SPINRAZA - UNITED STATES**: 625,700,000 US dollars - **SPINRAZA - Rest of World**: 947,500,000 US dollars - **TECFIDERA - UNITED STATES**: 169,200,000 US dollars - **TECFIDERA - Rest of World**: 797,900,000 US dollars - **TOFIDENCE - UNITED STATES**: 1,100,000 US dollars - **TOFIDENCE - Rest of World**: 0 US dollars - **TYSABRI product - UNITED STATES**: 920,000,000 US dollars - **TYSABRI product - Rest of World**: 795,000,000 US dollars - **VUMERITY - UNITED STATES**: 538,600,000 US dollars - **VUMERITY - Rest of World**: 89,400,000 US dollars - **ZURZUVAE - UNITED STATES**: 72,200,000 US dollars - **ZURZUVAE - Rest of World**: 0 US dollars - **Product revenue, net - UNITED STATES**: 3,237,300,000 US dollars - **Product revenue, net - Rest of World**: 3,976,200,000 US dollars - **Research and development**: 2,041,800,000 US dollars - **Selling, general and administrative**: 2,403,700,000 US dollars - **Amortization and impairment of acquired intangible assets**: 446,700,000 US dollars - **Gain on sale of priority review voucher, net**: negative 88,600,000 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 254,400,000 US dollars - **Gain on sale of building, net**: 0 US dollars - **Other (income) expense, net**: 343,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 27,700,000 US dollars - **Restructuring charges**: 30,200,000 US dollars - **Revenue before reconciliation (calculated)**: 24,203,600,000 US dollars. Sum of the reported revenue categories before the separately reported reconciliation. - **Components above reported revenue (calculated)**: negative 14,527,700,000 US dollars. The disclosed components add up to more than reported revenue; this is the difference, calculated, not a reported item. - **Equity in (income) loss of investee, net of tax**: 0 US dollars. Reported below-tax contribution to net income. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income. - Reported revenue categories plus the separately reported signed reconciliation equals consolidated revenue. ## Chart details: Revenue by Product and Service (2) - Page: https://plicit.ai/financials/biib/fy2024-annual-income-statement/revenue-by-product-and-service-2 - Chart image: https://plicit.ai/charts/biib-fy2024-annual-revenue-by-product-and-service-2-sankey.png Income statement for 2024-01-01 through 2024-12-31. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,675,900,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,310,400,000 US dollars - **Gross profit (calculated)**: 7,365,500,000 US dollars - **Operating expenses (calculated)**: 5,459,500,000 US dollars - **Operating profit (calculated)**: 1,906,000,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax**: 1,906,000,000 US dollars - **Income tax (benefit) expense**: 273,800,000 US dollars - **Net income**: 1,632,200,000 US dollars - **Product revenue, net**: 7,213,500,000 US dollars - **Revenue from anti-CD20 therapeutic programs**: 1,749,900,000 US dollars - **Alzheimer's collaboration revenue**: 59,900,000 US dollars - **Contract manufacturing, royalty and other revenue**: 652,600,000 US dollars - **Research and development**: 2,041,800,000 US dollars - **Selling, general and administrative**: 2,403,700,000 US dollars - **Amortization and impairment of acquired intangible assets**: 446,700,000 US dollars - **Gain on sale of priority review voucher, net**: negative 88,600,000 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 254,400,000 US dollars - **Gain on sale of building, net**: 0 US dollars - **Other (income) expense, net**: 343,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 27,700,000 US dollars - **Restructuring charges**: 30,200,000 US dollars - **Equity in (income) loss of investee, net of tax**: 0 US dollars. Reported below-tax contribution to net income. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income. ## Chart details: Revenue by Product and Service (3) - Page: https://plicit.ai/financials/biib/fy2024-annual-income-statement/revenue-by-product-and-service-3 - Chart image: https://plicit.ai/charts/biib-fy2024-annual-revenue-by-product-and-service-3-sankey.png Income statement for 2024-01-01 through 2024-12-31. View: Product and service (Other Revenues). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,675,900,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,310,400,000 US dollars - **Gross profit (calculated)**: 7,365,500,000 US dollars - **Operating expenses (calculated)**: 5,459,500,000 US dollars - **Operating profit (calculated)**: 1,906,000,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax**: 1,906,000,000 US dollars - **Income tax (benefit) expense**: 273,800,000 US dollars - **Net income**: 1,632,200,000 US dollars - **Contract manufacturing revenue**: 592,100,000 US dollars - **Royalty and other revenue**: 60,500,000 US dollars - **Contract manufacturing, royalty and other revenue**: 652,600,000 US dollars - **BENEPALI**: 479,100,000 US dollars - **IMRALDI**: 213,100,000 US dollars - **PLEGRIDY**: 260,500,000 US dollars - **Revenue from anti-CD20 therapeutic programs**: 1,749,900,000 US dollars - **Royalty revenue on sales of OCREVUS**: 1,339,500,000 US dollars - **SPINRAZA**: 1,573,200,000 US dollars - **TECFIDERA**: 967,100,000 US dollars - **TOFIDENCE**: 1,100,000 US dollars - **TYSABRI product**: 1,715,000,000 US dollars - **ZURZUVAE**: 72,200,000 US dollars - **Research and development**: 2,041,800,000 US dollars - **Selling, general and administrative**: 2,403,700,000 US dollars - **Amortization and impairment of acquired intangible assets**: 446,700,000 US dollars - **Gain on sale of priority review voucher, net**: negative 88,600,000 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 254,400,000 US dollars - **Gain on sale of building, net**: 0 US dollars - **Other (income) expense, net**: 343,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 27,700,000 US dollars - **Restructuring charges**: 30,200,000 US dollars - **Equity in (income) loss of investee, net of tax**: 0 US dollars. Reported below-tax contribution to net income. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income. ## Chart details: Revenue by Product and Service (5) - Page: https://plicit.ai/financials/biib/fy2024-annual-income-statement/revenue-by-product-and-service-5 - Chart image: https://plicit.ai/charts/biib-fy2024-annual-revenue-by-product-and-service-5-sankey.png Income statement for 2024-01-01 through 2024-12-31. View: Product and service (Additional Segment Information). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,675,900,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,310,400,000 US dollars - **Gross profit (calculated)**: 7,365,500,000 US dollars - **Operating expenses (calculated)**: 5,459,500,000 US dollars - **Operating profit (calculated)**: 1,906,000,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax**: 1,906,000,000 US dollars - **Income tax (benefit) expense**: 273,800,000 US dollars - **Net income**: 1,632,200,000 US dollars - **Product revenue, net**: 7,213,500,000 US dollars - **Royalty and other revenue**: 60,500,000 US dollars - **Alzheimer's collaboration revenue**: 59,900,000 US dollars - **Contract manufacturing revenue**: 592,100,000 US dollars - **Revenue from anti-CD20 therapeutic programs**: 1,749,900,000 US dollars - **Research and development**: 2,041,800,000 US dollars - **Selling, general and administrative**: 2,403,700,000 US dollars - **Amortization and impairment of acquired intangible assets**: 446,700,000 US dollars - **Gain on sale of priority review voucher, net**: negative 88,600,000 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 254,400,000 US dollars - **Gain on sale of building, net**: 0 US dollars - **Other (income) expense, net**: 343,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 27,700,000 US dollars - **Restructuring charges**: 30,200,000 US dollars - **Equity in (income) loss of investee, net of tax**: 0 US dollars. Reported below-tax contribution to net income. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income. ## Chart details: Revenue by Business Segment by Product and Service - Page: https://plicit.ai/financials/biib/fy2024-annual-income-statement/revenue-by-business-segment-by-product-and-service - Chart image: https://plicit.ai/charts/biib-fy2024-annual-revenue-by-business-segment-by-product-and-service-sankey.png Income statement for 2024-01-01 through 2024-12-31. View: Segments by Product and Service. Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,675,900,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,310,400,000 US dollars - **Gross profit (calculated)**: 7,365,500,000 US dollars - **Operating expenses (calculated)**: 5,459,500,000 US dollars - **Operating profit (calculated)**: 1,906,000,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax**: 1,906,000,000 US dollars - **Income tax (benefit) expense**: 273,800,000 US dollars - **Net income**: 1,632,200,000 US dollars - **Reportable Segment - Contract manufacturing, royalty and other revenue**: 652,600,000 US dollars - **Reportable Segment - Revenue from anti-CD20 therapeutic programs**: 1,749,900,000 US dollars - **Undisclosed (calculated)**: 7,273,400,000 US dollars - **Research and development**: 2,041,800,000 US dollars - **Selling, general and administrative**: 2,403,700,000 US dollars - **Amortization and impairment of acquired intangible assets**: 446,700,000 US dollars - **Gain on sale of priority review voucher, net**: negative 88,600,000 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 254,400,000 US dollars - **Gain on sale of building, net**: 0 US dollars - **Other (income) expense, net**: 343,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 27,700,000 US dollars - **Restructuring charges**: 30,200,000 US dollars - **Equity in (income) loss of investee, net of tax**: 0 US dollars. Reported below-tax contribution to net income. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income. ## Chart details: Revenue by Product and Service (4) - Page: https://plicit.ai/financials/biib/fy2024-annual-income-statement/revenue-by-product-and-service-4 - Chart image: https://plicit.ai/charts/biib-fy2024-annual-revenue-by-product-and-service-4-sankey.png Income statement for 2024-01-01 through 2024-12-31. View: Product and service (Narrative). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,675,900,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,310,400,000 US dollars - **Gross profit (calculated)**: 7,365,500,000 US dollars - **Operating expenses (calculated)**: 5,459,500,000 US dollars - **Operating profit (calculated)**: 1,906,000,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax**: 1,906,000,000 US dollars - **Income tax (benefit) expense**: 273,800,000 US dollars - **Net income**: 1,632,200,000 US dollars - **Contract manufacturing revenue**: 592,100,000 US dollars - **Alzheimer's collaboration revenue**: 59,900,000 US dollars - **AVONEX**: 707,500,000 US dollars - **BENEPALI**: 479,100,000 US dollars - **BYOOVIZ**: 36,600,000 US dollars - **FLIXABI**: 63,200,000 US dollars - **FUMADERM And ADUHELM**: 10,300,000 US dollars - **Revenue from anti-CD20 therapeutic programs**: 1,749,900,000 US dollars - **Royalty revenue on sales of OCREVUS**: 1,339,500,000 US dollars - **Completed technology for SKYCLARYS (U.S.)**: 382,500,000 US dollars - **SPINRAZA**: 1,573,200,000 US dollars - **TECFIDERA**: 967,100,000 US dollars - **TYSABRI product**: 1,715,000,000 US dollars - **Research and development**: 2,041,800,000 US dollars - **Selling, general and administrative**: 2,403,700,000 US dollars - **Amortization and impairment of acquired intangible assets**: 446,700,000 US dollars - **Gain on sale of priority review voucher, net**: negative 88,600,000 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 254,400,000 US dollars - **Gain on sale of building, net**: 0 US dollars - **Other (income) expense, net**: 343,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 27,700,000 US dollars - **Restructuring charges**: 30,200,000 US dollars - **Equity in (income) loss of investee, net of tax**: 0 US dollars. Reported below-tax contribution to net income. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income. ## Chart details: Revenue by Product and Service - Page: https://plicit.ai/financials/biib/fy2024-annual-income-statement/revenue-by-product-and-service - Chart image: https://plicit.ai/charts/biib-fy2024-annual-revenue-by-product-and-service-sankey.png Income statement for 2024-01-01 through 2024-12-31. View: Product and service (Revenues by Product). Revenue uses this breakdown; costs and expenses retain the consolidated categories. - **Revenues**: 9,675,900,000 US dollars - **Cost of sales, excluding amortization and impairment of acquired intangible assets**: 2,310,400,000 US dollars - **Gross profit (calculated)**: 7,365,500,000 US dollars - **Operating expenses (calculated)**: 5,459,500,000 US dollars - **Operating profit (calculated)**: 1,906,000,000 US dollars - **Other income (expense), net (calculated)**: 0 US dollars - **Income before income tax (benefit) expense and equity in (income) loss of investee, net of tax**: 1,906,000,000 US dollars - **Income tax (benefit) expense**: 273,800,000 US dollars - **Net income**: 1,632,200,000 US dollars - **BENEPALI**: 479,100,000 US dollars - **IMRALDI**: 213,100,000 US dollars - **FLIXABI**: 63,200,000 US dollars - **BYOOVIZ**: 36,600,000 US dollars - **TOFIDENCE**: 1,100,000 US dollars - **TECFIDERA**: 967,100,000 US dollars - **VUMERITY**: 628,000,000 US dollars - **AVONEX**: 707,500,000 US dollars - **PLEGRIDY**: 260,500,000 US dollars - **TYSABRI product**: 1,715,000,000 US dollars - **FAMPYRA**: 71,700,000 US dollars - **ZURZUVAE**: 72,200,000 US dollars - **FUMADERM And ADUHELM**: 10,300,000 US dollars - **SPINRAZA**: 1,573,200,000 US dollars - **QALSODY**: 32,400,000 US dollars - **SKYCLARYS**: 382,500,000 US dollars - **Alzheimer's collaboration revenue**: 59,900,000 US dollars - **Contract manufacturing, royalty and other revenue**: 652,600,000 US dollars - **Revenue from anti-CD20 therapeutic programs**: 1,749,900,000 US dollars - **Research and development**: 2,041,800,000 US dollars - **Selling, general and administrative**: 2,403,700,000 US dollars - **Amortization and impairment of acquired intangible assets**: 446,700,000 US dollars - **Gain on sale of priority review voucher, net**: negative 88,600,000 US dollars - **Collaboration profit sharing/(loss reimbursement)**: 254,400,000 US dollars - **Gain on sale of building, net**: 0 US dollars - **Other (income) expense, net**: 343,600,000 US dollars - **(Gain) loss on fair value remeasurement of contingent consideration**: 27,700,000 US dollars - **Restructuring charges**: 30,200,000 US dollars - **Equity in (income) loss of investee, net of tax**: 0 US dollars. Reported below-tax contribution to net income. ### Chart connections - Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income. - Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit, plus the explicitly reported below-tax contributions, equals net income.